Javascript must be enabled to continue!
VHL ligand binding increases intracellular level of VHL
View through CrossRef
Abstract
The von–Hippel Lindau (VHL) protein is a tumour suppressor protein frequently mutated in the VHL disease, which functions as substrate recognition subunit of a Cul2 E3 ubiquitin ligase (CRL2
VHL
). CRL2
VHL
plays an important role in oxygen sensing, by binding and targeting Hypoxia Inducible Factor-alpha subunits (HIF-alpha) for ubiquitination and degradation. VHL is also commonly hijacked by heterobifunctional degrader molecules known as proteolysis-targeting chimeras (PROTACs). In previous work we reported the structure-based design and functional characterisation of VHL inhibitors (VH032 and VH298) that induce the HIF response in cells. Here, we use unbiased quantitative mass spectrometry to identify the proteomic changes elicited by the VHL inhibitor and compare this to hypoxia or broad-spectrum prolyl-hydroxylase domain (PHD) enzyme inhibitor IOX2. Our results demonstrate the VHL inhibitor selectively activates the HIF response that is also present in the hypoxia- and IOX2-induced proteomic changes. Interestingly, VHL inhibitors were found to selectively upregulate a single protein, which is VHL itself. Our analysis revealed that this occurs via protein stabilisation of VHL isoforms and not via changes in transcript levels. Increased VHL levels upon VH298 treatment resulted in turn to reduced levels of HIF-1α protein. Our results demonstrate the high specificity of VHL inhibitors and suggest that use of these inhibitors would not produce overtly side effects due to prolonged HIF stabilisation. They also exemplify the concept that small-molecule binding induced protein stabilisation can increase protein levels inside cells.
Title: VHL ligand binding increases intracellular level of VHL
Description:
Abstract
The von–Hippel Lindau (VHL) protein is a tumour suppressor protein frequently mutated in the VHL disease, which functions as substrate recognition subunit of a Cul2 E3 ubiquitin ligase (CRL2
VHL
).
CRL2
VHL
plays an important role in oxygen sensing, by binding and targeting Hypoxia Inducible Factor-alpha subunits (HIF-alpha) for ubiquitination and degradation.
VHL is also commonly hijacked by heterobifunctional degrader molecules known as proteolysis-targeting chimeras (PROTACs).
In previous work we reported the structure-based design and functional characterisation of VHL inhibitors (VH032 and VH298) that induce the HIF response in cells.
Here, we use unbiased quantitative mass spectrometry to identify the proteomic changes elicited by the VHL inhibitor and compare this to hypoxia or broad-spectrum prolyl-hydroxylase domain (PHD) enzyme inhibitor IOX2.
Our results demonstrate the VHL inhibitor selectively activates the HIF response that is also present in the hypoxia- and IOX2-induced proteomic changes.
Interestingly, VHL inhibitors were found to selectively upregulate a single protein, which is VHL itself.
Our analysis revealed that this occurs via protein stabilisation of VHL isoforms and not via changes in transcript levels.
Increased VHL levels upon VH298 treatment resulted in turn to reduced levels of HIF-1α protein.
Our results demonstrate the high specificity of VHL inhibitors and suggest that use of these inhibitors would not produce overtly side effects due to prolonged HIF stabilisation.
They also exemplify the concept that small-molecule binding induced protein stabilisation can increase protein levels inside cells.
Related Results
Rôle de la nouvelle isoforme d’épissage du gène von Hippel-Lindau dans la survenue d’érythrocytoses et de cancers du rein héréditaires
Rôle de la nouvelle isoforme d’épissage du gène von Hippel-Lindau dans la survenue d’érythrocytoses et de cancers du rein héréditaires
La protéine von Hippel-Lindau (VHL), codée par le gène VHL constitué de 3 exons, est un facteur clé de la régulation de la voie de l’hypoxie dont l’acteur majeur est le facteur de ...
Abstract 1815: Transcriptomic profiling of VHL-dependent long noncoding RNAs in clear cell renal cell carcinoma
Abstract 1815: Transcriptomic profiling of VHL-dependent long noncoding RNAs in clear cell renal cell carcinoma
Abstract
INTRODUCTION: Clear cell renal cell carcinoma (ccRCC), the most common subtype of kidney cancer, carries a poor prognosis, with an estimated median overa...
7
th
International Symposium on Enabling Technologies for Life Sciences (ETP)
7
th
International Symposium on Enabling Technologies for Life Sciences (ETP)
The seventh in the series of ETP Symposia (see
Rapid Communications in Mass Spectrometry
2012,
26
, ...
Abstract 2300: Novel conditional knockout of VHL in the kidney leads to precancerous lesions that exhibit an inflammatory response.
Abstract 2300: Novel conditional knockout of VHL in the kidney leads to precancerous lesions that exhibit an inflammatory response.
Abstract
Mutations of the tumor suppressor gene von Hippel-Lindau (VHL) can lead to benign and malignant tumors, including the devastating cancer clear-cell renal ce...
Abstract Wed061: An Inducible Genetic Model of Chronic Cardiomyocyte-specific Hypoxic Signaling Elicits Rapid Cardiac Remodeling
Abstract Wed061: An Inducible Genetic Model of Chronic Cardiomyocyte-specific Hypoxic Signaling Elicits Rapid Cardiac Remodeling
Background:
Cardiovascular disease is the leading cause of death in the United States, with a continuing need to understand molecular mechanisms of heart failure and ar...
Sequence, structure, dynamics, and substrate specificity analyses of bacterial Glycoside Hydrolase 1 enzymes from several activities
Sequence, structure, dynamics, and substrate specificity analyses of bacterial Glycoside Hydrolase 1 enzymes from several activities
Glycoside hydrolase 1 (GH1) enzymes are a ubiquitous family of enzymes that hydrolyse the glycosidic bond between two or more carbohydrates, or between a carbohydrate and a non-car...
FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells
FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells
FLT3 ligand is a hematopoietic growth factor that plays a key role in growth of primitive hematopoietic cells. FLT3 receptor mRNA is found in early hematopoietic progenitors and in...
Confinement of unliganded EGFR by tetraspanin nanodomains gates EGFR ligand binding and signaling
Confinement of unliganded EGFR by tetraspanin nanodomains gates EGFR ligand binding and signaling
Abstract
The epidermal growth factor receptor (EGFR) is a central regulator of cell physiology. EGFR is activated by ligand binding, triggering receptor dimerizatio...

